💡 Did you know?
The BSE, founded in 1875, is Asia's oldest stock exchange — it started under a banyan tree on Dalal Street, where the bronze bull stands today.
History
The BSE, founded in 1875, is Asia's oldest stock exchange — it started under a banyan tree on Dalal Street, where the bronze bull stands today.
The BSE, founded in 1875, is Asia's oldest stock exchange — it started under a banyan tree on Dalal Street, where the bronze bull stands today.
Themis Medicare Limited is a research-based pharmaceutical company, which is engaged in the manufacturing of pharmaceutical products, especially in formulation and active pharmaceutical ingredients (API) activity. The Company operates through one segment: Pharmaceuticals. The…
Weekly engine runs — movement reflects the numbers, not analyst opinion.
A middling, stagnant business, trading cheap versus its own history — but flagged on governance.
THEMIS MEDICARE LTD. is scored on the pharma / healthcare framework. It keeps a thin 0.3% of every rupee of sales as net profit. Cash conversion lags the reported profit (CFO/PAT -2.87×) — worth a closer look. Free cash flow is worth about -0.6% of its market value.
Over the last 3 years revenue compounded at -1%/yr and profit at -73%/yr. Book value has grown 6%/yr. Return on equity is a weak 0.4%. In the latest quarter profit grew 177% versus the prior quarter.
At 22× earnings, the stock sits at the 1st percentile of its own 3-year range — the cheap end of where it has historically traded. Today's price implies ~11%/yr earnings growth for a decade. The forensic screen raises a red flag: 485% of pre-tax profit is other income, not operations.
A plain-English restatement of the figures on this page — rules-based, for education and research context, not investment advice or a recommendation.
| Ratio | Company | Sector | Read |
|---|---|---|---|
| P/E | 23.45 | — | — |
| P/B | 2.56 | 4.1 | better |
| EV/EBITDA | 13.5 | 19.33 | better |
| ROE | 0.42 | 0.3 | better |
| ROCE | 2.7 | 14.41 | worse |
| ROA | 6.68 | 1.64 | better |
| Quick Ratio | 1.35 | 4.8 | worse |
| Peer | P/E | P/B | ROE |
|---|---|---|---|
| Sun Pharmaceutical Industries | 40.6 | 5.0 | 13.8% |
| Divis Laboratories | 93.5 | 16.3 | 15.3% |
| Torrent Pharmaceuticals | 85.9 | 9.8 | 11.4% |
Revenue is on a 2-year growth streak. Negative CAGR — the top line has shrunk over this window. Growth is decelerating — latest year grew slower than the year before.
Revenue is outpacing profit (-1% vs -73%) — costs are rising faster than the top line. The latest year saw a -96% swing — check if it's a one-off or structural.
Operating margin has compressed from 20% to 1% — costs or competition are eating into profitability. Interest or tax burden is shrinking — more of the operating profit is reaching the bottom line. Margins have declined for 3 consecutive years — watch for a structural cost problem.
ROE at 0% — modest; the capital isn't working hard. Capital efficiency declining — ROE down 16pp.
EPS dropped in the latest year despite possible profit changes — dilution or a profit dip could be at play. -73% EPS CAGR — this is the rate at which each share's claim on earnings is compounding.
1 of 4 years had negative operating cash flow — profitability on paper may not translate to cash. Investing outflows exceed operating cash — the company relies on external funding to finance expansion.
When operating cash keeps pace with reported profit, earnings are cash-backed; a persistent shortfall is a quality flag.
Revenue rose 10% sequentially — momentum is building.
1 of 4 quarters loss-making — quarterly profitability is uneven. Profit jumped 177% QoQ — check if this is operating leverage or a one-off item. Quarterly net margins are expanding (-4% → 28%) — profitability per rupee of revenue is improving.
How today's P/E compares to the stock's own historical range. Dashed line = the 3y median.
Promoters hold 67.1% — heavily owner-operated with strong skin in the game.
Produced by a rules-based engine over licensed exchange fundamentals — every sentence above is derived from the numbers shown, no analyst or AI opinion involved. Education and research context, not investment advice. We are not SEBI-registered as an Investment Adviser or Research Analyst.